Clinical Trial

First Line Treatment With Olaparib in Combination With Bevacizumab in HRD Positive Patients

Study acronym: IOLANTHE
Active, Not Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
The goal of this prospective, phase IV, multi-centre clinical trial is to to define the proportion of patients with advanced high grade epithelial ovarian cancer (EOC) HRD-positive who will be treated at first line with olaparib in combination with bevacizumab as maintenance and to describe their clinical and demographic characteristics. Other primary objective is to confirm, in a setting close to clinical practice, the efficacy of olaparib concomitant with bevacizumab as maintenance treatment after first-line chemotherapy in patients with advanced high grade EOC HRD-positive and who have received bevacizumab in combination with chemotherapy.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2023-11-02; most recent amendment 2026-06-22.
Status change: Recruiting → Active, Not Recruiting 2025-09-11
Trial Details
NCT Number NCT06121401
Lead Sponsor Mario Negri Institute for Pharmacological Research
Collaborators: AstraZeneca
Conditions Carcinoma, Ovarian Epithelial
Enrollment 190 participants
Start Date 2023-09-15
Primary Completion 2027-03-15 (estimated)
Study Completion 2027-09-15 (estimated)
Updated on ClinicalTrials.gov 2026-06-25